HIGHLIGHTS:
-
Pivalate achieves positive Phase 2a data in brain mets trial
-
Joint venture with MD Anderson to develop novel pharmaceuticals
-
FDA grants orphan drug status and rare pediatric disease designation for DUNP19 treatment for osteosarcoma
-
Entitlement offer raising $10m
-
Strategic agreements with Lantheus and NanoMab
-
GenesisCare agreements extended to prostate cancer trial
-
Clinical supply agreement announced with SHINE Technologies
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended 30 September 2022.
For more information, download the attached PDF.
Download this document
